Plus Therapeutics unit signs national coverage deal with Elevance Health

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/27/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. META
7. FICO
8. CART
9. LLY
10. TSLA

Go back to Plus Therapeutics unit signs national coverage deal with Elevance Health

Plus Therapeutics Secures National Coverage Agreement with Elevance Health for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer

June 25, 2026 7:30 AM EDT

HOUSTON, June 25, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (Plus or the Company), announced today that it has signed a national agreement with Elevance Health, Inc. (NYSE: ELV), effective May 1, 2026, covering approximately 45.4 million people throughout the United States, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings CNSide CSF TCE assay total contracted coverage to 126 million people.

The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The... More